Join Drs Benjamin Schlechter and Harvey Mamon as they discuss treatment options for patients with stage II and III rectal cancer based on new data from the most recent clinical trial results. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/988971). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Colon Cancer https://emedicine.medscape.com/article/277496-overview Colon Cancer Staging https://emedicine.medscape.com/article/2006674-overview Signal Transduction https://www.cancer.gov/publications/dictionaries/cancer-terms/def/signal-transduction Preoperative Treatment of Locally Advanced Rectal Cancer https://pubmed.ncbi.nlm.nih.gov/37272534/ Neoadjuvant Chemotherapy Without Routine Use of Radiation Therapy for Patients With Locally Advanced Rectal Cancer: A Pilot Trial https://pubmed.ncbi.nlm.nih.gov/24419115/ FOLFOX Regimen https://www.cancer.gov/publications/dictionaries/cancer-terms/def/folfox-regimen Cancer Therapy Evaluation Program https://ctep.cancer.gov/ Common Terminology Criteria for Adverse Events (CTCAE) v5.0 https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf Patient-Reported Outcomes During and After Treatment for Locally Advanced Rectal Cancer in the PROSPECT Trial (Alliance N1048) https://pubmed.ncbi.nlm.nih.gov/37270691/ Abdominoperineal Resection https://www.ncbi.nlm.nih.gov/books/NBK574568/ The Circumferential Resection Margin Is a Prognostic Predictor in Colon Cancer https://pubmed.ncbi.nlm.nih.gov/32670875/ Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy https://pubmed.ncbi.nlm.nih.gov/35483010/ Total Neoadjuvant Therapy (TNT) Versus Standard Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer: A Systematic Review and Meta-Analysis https://pubmed.ncbi.nlm.nih.gov/33987952/ Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation (JANUS) https://classic.clinicaltrials.gov/ct2/show/NCT05610163 Factors Influencing Downstaging After Neoadjuvant Long-Course Chemoradiotherapy in Rectal Carcinoma https://pubmed.ncbi.nlm.nih.gov/35545701/ Carcinoembryonic Antigen https://www.ncbi.nlm.nih.gov/books/NBK578172/ Short-Course Radiotherapy Followed by Chemotherapy Before Total Mesorectal Excision (TME) Versus Preoperative Chemoradiotherapy, TME, and Optional Adjuvant Chemotherapy in Locally Advanced Rectal Cancer (RAPIDO): A Randomised, Open-Label, Phase 3 Trial https://pubmed.ncbi.nlm.nih.gov/33301740/ Neoadjuvant Chemotherapy With FOLFIRINOX and Preoperative Chemoradiotherapy for Patients With Locally Advanced Rectal Cancer (UNICANCER-PRODIGE 23): A Multicentre, Randomised, Open-Label, Phase 3 Trial https://pubmed.ncbi.nlm.nih.gov/33862000/ FOLFIRINOX Regimen https://www.cancer.gov/publications/dictionaries/cancer-terms/def/folfirinox-regimen Locoregional Failure During and After Short-Course Radiotherapy Followed by Chemotherapy and Surgery Compared to Long-Course Chemoradiotherapy and Surgery - A Five-Year Follow-Up of the RAPIDO Trial https://pubmed.ncbi.nlm.nih.gov/36661037/

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related